Medical countermeasures (MCMs) to treat patients with radiation-induced myelosuppression following a radiological/nuclear incident
March 30th, 2018MCMs to treat patients with radiation-induced myelosuppression following a radiological/nuclear incident (H-ARS)
Myelosuppression occurs when radiation damages the bone marrow. Suppression of the bone marrow blocks the production of blood cells. There are FDA-approved products that can help patients with H-ARS by facilitating recovery of bone marrow cells that develop into white blood cells, including neutrophils, which help fight off infections.
FDA-approved products that may be used to treat adult and pediatric patients acutely exposed to myelosuppressive doses of radiation, a condition known as Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS:
- Neupogen (filgrastim) – approved March 2015 [more info; product label (PDF, 1.2 MB)]
- Neulasta (pegfilgrastim) – approved November 2015 [product label (PDF, 1.7 MB)]
- Leukine (sargramostim) – approved March 29, 2018 [more info (PDF, 299 KB); product label (PDF, 786 KB)]